Navigation Links
PARI Pharma Reports Successful Phase Ib Clinical Results for Inhaled Liposomal Cyclosporine A and Gains FDA Orphan Drug Designation for the Prevention and Treatment of Bronchiolitis Obliterans
Date:6/2/2009

ations, and therapies for upper and lower respiratory indications. PARI Pharma partners with pharmaceutical companies to develop new or improved therapies with eFlow Technology and other advanced delivery platforms. Investigational eFlow Nebulizer Systems are optimized and customized per investigational drug product and are currently in clinical trials for cystic fibrosis, asthma, COPD, respiratory syncytial virus (RSV) infection, and treatments for lung transplant patients among other indications.

PARI Pharma provides comprehensive inhalation drug development, including nebulizer formulation development and optimization, analytics, aerosol characterization, clinical protocol development, and regulatory guidance, all in compliance with CMC/GCP guidelines. PARI Pharma has several clinical development programs ongoing, either partnered or on its own. Proprietary programs in different development stages will be offered for licensing partnerships.

Online at www.paripharma.com


'/>"/>
SOURCE PARI Pharma
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. PharmAthene Submits Proposal to BARDA in Response to Broad Agency Announcement for Advanced Research and Development for Valortim(R)
2. Arena Pharmaceuticals Announces the Presentation of Lorcaserin Phase 3 BLOOM Data at the American Diabetes Associations 69th Scientific Sessions
3. Neurobiological Technologies Partner, Celtic Pharma, Announces Results of XERECEPT(R) Phase 3 Clinical Program
4. Keryx Biopharmaceuticals Announces Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer
5. Keryx Biopharmaceuticals Reports Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer
6. Keryx Biopharmaceuticals Reports Single Agent Phase 2 Data of KRX-0401 (Perifosine) Further Demonstrating KRX-0401s Activity in the Treatment of Advanced Metastatic Renal Cell Cancer
7. Catalyst Pharmaceutical Partners Announces Top-Line Results of CPP-109 Phase II Trial for Cocaine Addiction
8. Poniard Pharmaceuticals Announces Progression-Free Survival Data From Phase 2 Clinical Trial of Picoplatin in Metastatic Colorectal Cancer
9. BioCis Pharma Starts a Phase I Clinical Trial With a New Cancer Drug
10. Kinex Pharmaceuticals To Present at ASCO 2009 Annual Meeting
11. TRACON Pharmaceuticals Small Molecule TRC102 and Antibody TRC105 to be Presented at ASCO 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... , Inc. (NASDAQ: BIOS ) announced today that ... at the Bank of America Merrill Lynch 2014 Leveraged Finance Conference ... , Wednesday, December 3, 2014 , , , , Time: ... Location: , , , Boca Raton Resort and Club, Florida , ... BioScrip, Inc. is a leading national provider of infusion and ...
(Date:11/26/2014)... -- Zynerba Pharmaceuticals , Inc., a specialty pharmaceutical ... cannabinoid treatments, today announced that the company will present ... The conference will be held December 2 to 3, ... York . Zynerba,s Chairman and CEO, Armando ... December 2. To listen to a webcast ...
(Date:11/26/2014)... , Nov. 26, 2014  Aridis Pharmaceuticals, ... produce novel therapies for infectious diseases, announced today ... an internationally recognized key opinion leader in the ... scientific advisory board. Founder and Chief ... "We believe Dr. Opal,s extensive experience investigating bacterial ...
Breaking Medicine Technology:Zynerba Pharmaceuticals to Present at Piper Jaffray 26th Annual Healthcare Conference 2014 2Aridis Pharmaceuticals Appoints Dr. Steven Opal to Scientific Advisory Board 2Aridis Pharmaceuticals Appoints Dr. Steven Opal to Scientific Advisory Board 3
... /PRNewswire-Asia-FirstCall/ -- 3SBio Inc. (NASDAQ: SSRX ) ... focused on researching, developing, manufacturing and marketing biopharmaceutical products, ... quarter and first half ended June 30, 2011. ... Total net revenues increased by 29.0% over the ...
... 2011 Vycor Medical, Inc. ("Vycor" or the "Company") ... fiscal quarter ended March 31, 2011, the year ended ... 2010, June 30, 2010 and September 30, 2010 and ... Company,s periodic reports filed with the Securities and Exchange ...
Cached Medicine Technology:3SBio Inc. Announces Unaudited Second Quarter and First Half 2011 Results 23SBio Inc. Announces Unaudited Second Quarter and First Half 2011 Results 33SBio Inc. Announces Unaudited Second Quarter and First Half 2011 Results 43SBio Inc. Announces Unaudited Second Quarter and First Half 2011 Results 53SBio Inc. Announces Unaudited Second Quarter and First Half 2011 Results 63SBio Inc. Announces Unaudited Second Quarter and First Half 2011 Results 73SBio Inc. Announces Unaudited Second Quarter and First Half 2011 Results 83SBio Inc. Announces Unaudited Second Quarter and First Half 2011 Results 93SBio Inc. Announces Unaudited Second Quarter and First Half 2011 Results 103SBio Inc. Announces Unaudited Second Quarter and First Half 2011 Results 113SBio Inc. Announces Unaudited Second Quarter and First Half 2011 Results 123SBio Inc. Announces Unaudited Second Quarter and First Half 2011 Results 133SBio Inc. Announces Unaudited Second Quarter and First Half 2011 Results 143SBio Inc. Announces Unaudited Second Quarter and First Half 2011 Results 153SBio Inc. Announces Unaudited Second Quarter and First Half 2011 Results 163SBio Inc. Announces Unaudited Second Quarter and First Half 2011 Results 173SBio Inc. Announces Unaudited Second Quarter and First Half 2011 Results 183SBio Inc. Announces Unaudited Second Quarter and First Half 2011 Results 19Vycor Medical, Inc. Restatement of Financial Statements 2Vycor Medical, Inc. Restatement of Financial Statements 3
(Date:11/28/2014)... (PRWEB) November 28, 2014 The ... techniques such as Dynamic Neuromuscular Stabilization, Extracorporeal Shock ... analysis. After moving to upgraded facilities in 2011, ... clinic. Now, owner Dr. Lev Kalika has launched ... injury prevention lab in the country. , The ...
(Date:11/28/2014)... The holiday season is fast approaching. As ... new collection of fashionable party dresses. What’s more, the company ... these brand new outfits; the special offer is valid until ... online supplier and it has received a lot of requests ... specially designed to flatter various body shapes; they are available ...
(Date:11/28/2014)... Brosix is always making changes to its infrastructure architecture ... efficient, effective, and secure experience. Most recently, the company ... ability to setup local servers for each country or ... around the globe. , 2. The ability to setup ... require millions of users in one network. , 3. ...
(Date:11/28/2014)... Orlando, FL (PRWEB) November 28, 2014 ... management solutions, announced its Release v5.1 which provides ... and enhanced workflow options. , “As we ... we continue to provide more functionality and improved ... states Robert Gambotz, CEO for Novatus. “With the ...
(Date:11/28/2014)... 2014 Dr. Diane Walder, one of ... treatment to her practice called Ultrashape that is designed to ... inches in just six weeks. Ultrashape has been praised by ... in results when compared to other types of external fat ... it,” said Dr. Walder. , According to Dr. Walder, ...
Breaking Medicine News(10 mins):Health News:New York Dynamic Neuromuscular Rehabilitation Opens Nation's Most Advanced Movement Performance and Injury Prevention Lab 2Health News:New York Dynamic Neuromuscular Rehabilitation Opens Nation's Most Advanced Movement Performance and Injury Prevention Lab 3Health News:Trendy Party Dresses For The Coming Holiday Season From Balfleet.com 2Health News:Brosix Infrastructure Architecture Changes to Benefit Users 2Health News:Novatus Releases v5.1 with New Advanced Reporting Capabilities 2Health News:Dr. Diane Walder Introduces New Fat Reduction Treatment Called Ultrashape 2Health News:Dr. Diane Walder Introduces New Fat Reduction Treatment Called Ultrashape 3
... Madhya Pradesh government has decided to implement a new ... through several 'anganwadis' (mother and child care centres). ... years are in full swing in the 59,324 anganwadis. ... an official of the women and child welfare department. ...
... better for children suffering from asthma compared to ... effectiveness and safety of different medicines. ... children control asthma, clinical trials directly comparing them ... Medical. ,For the first time, researchers ...
... review in the current issue of the Cochrane Library journal ... (ED) - Cialis, Levitra and Viagra appear to be safe ... in a family of medications called phosphodiesterase type 5 (PDE-5) ... of ED. Experts have estimated that the diabetic men ...
... talk of HIV/AIDS falling on deaf ears? ‘Careless’ is perhaps too ... to be completely in-charge of their lives, yet throw caution to ... survey has shown that, nearly three out of four women, do ... ,The Body Shop and MTV got together for a ...
... Schering-Plough fungus-fighter drug - Noxafil, //which gained FDA approval ... with crippled immune systems, according to two studies financed ... were published in the New England Journal of Medicine. ... known generically as posaconazole, also seems to have fewer ...
... all set to tighten the screws on smoking and ... hearing starting on Jan 23, is scheduled in which ... before the committee. ,Under the original act ... sports and other popular events by tobacco companies is ...
Cached Medicine News:Health News:ED Drugs - Safe and Effective for Diabetic Men 2
... Centuries of German Craftsmanship have ... in the world. Ocutek® now ... Only holders of the coveted ... eight-year apprenticeship, are qualified to ...
... of German Craftsmanship have produced ... the world. Ocutek® now makes ... holders of the coveted Meisterbrief ... apprenticeship, are qualified to become ...
... Craftsmanship have produced the finest ... Ocutek now makes them available ... the coveted Meisterbrief certificate, which ... qualified to become Ocutek instrument ...
1mm by 7mm horizontal punch. Flat serrated handle. Overall length 87mm....
Medicine Products: